logo
Money, sex and a Buddhist monk: Head of China's famed Shaolin Temple under investigation

Money, sex and a Buddhist monk: Head of China's famed Shaolin Temple under investigation

CNN5 days ago
China's famed Shaolin Temple announced on Sunday that its abbot is under investigation for suspected embezzlement and 'improper relationships' with women, reviving decade-old allegations against the controversial, high-profile monk.
Shi Yongxin, known as 'CEO monk' for his entrepreneurial endeavors that transformed the Buddhist monastery into a commercial empire, is suspected of criminal offenses including embezzlement and misappropriation of project funds and temple assets, the temple's authority said in a statement.
The 59-year-old monk was also accused of seriously violating Buddhist precepts by maintaining 'improper relationships' with multiple women over an extended period and fathering at least one child, according to the statement.
Buddhist monks in China have traditionally been expected to take a vow of celibacy.
'(Shi) is currently under joint investigation by multiple departments. Further information will be released to the public in due course,' the statement added.
CNN has not been able to contact Shi.
Established more than 1,500 years ago in the forested mountains of central China, the Shaolin Temple is both a religious and cultural icon, renowned for its age-old tradition of Zen Buddhism and Shaolin kung fu – a distinct form of Chinese martial arts.
Shi, who became the abbot of the Shaolin Temple in 1999 and was a member of China's rubber-stamp parliament for two decades, has frequently appeared in the media spotlight.
Known as the first Chinese abbot to hold a Master of Business Administration degree, he was often seen globetrotting with an iPhone in hand, meeting world leaders and industry titans – from the late Queen Elizabeth II of Great Britain, late South African president Nelson Mandela, and Henry Kissinger to Apple CEO Tim Cook.
In February, Shi led a delegation of monks from the Shaolin Temple to the Vatican to meet with Pope Francis.
But unflattering headlines have dogged the Buddhist monk for years – including his acceptance of a 1 million yuan ($140,000) car from the local government as a reward for promoting tourism in 2006.
Responding to a public outcry at the time, Shi told state media: 'Monks are also citizens. We have fulfilled our duties and made contributions to society, so it is only right that we receive rewards.'
His focus on promoting the Shaolin brand and turning it to multimillion-dollar business has attracted fierce criticism, especially from some followers who saw excessive commercialization as corrupting the spiritual integrity of the religious institution.
He staged Shaolin kung fu performances around the world, licensed the temple's name out to cartoons, movies and video games, and established a business empire that includes publishing, traditional Chinese medicine, tourist development and real estate.
For his part, Shi has defended his efforts to commercialize the Shaolin brand and promote it globally.
After writing a $3 million check to an Australian town in 2015 to build a Shaolin branch there, Shi Yongxin told state-run Xinhua news agency: 'If China can import Disney resorts, why can't other countries import the Shaolin Monastery?'
'Cultural promotion is a very dignified undertaking,' he said.
Later that year, a self-identified Shaolin insider posted a series of explosive allegations on Chinese social media, depicting Shi as an embezzler and womanizer with illegitimate children.
The accuser included documents dating back to the late 1980s purportedly showing Shi being kicked out of Shaolin following theft and other accusations from his own master. Among the documents posted online was a birth certificate for one of the abbot's supposed illegitimate children, as well as photos of the alleged mother and the child.
The allegations prompted an angry denial from the Shaolin Temple and an investigation from the country's religious affairs authorities. Asked by BBC Chinese at the time about the allegations, Shi said: 'If there were a problem, it would have surfaced long ago.'
The authorities dropped the case in 2017, citing insufficient evidence. Three years later, Shi went on to be re-elected as the deputy head of the Buddhist Association of China – the state supervisory body on the religion – a position he has held since 2002.
Steven Jiang contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pharma interest can plug NIH funding gap: Illumina CEO
Pharma interest can plug NIH funding gap: Illumina CEO

Yahoo

time2 hours ago

  • Yahoo

Pharma interest can plug NIH funding gap: Illumina CEO

Genetic sequencing company Illumina (ILMN) has had a rough few years. It has battled activist investors, faced off with the Federal Trade Commission, and, most recently, agreed to a $9.8 million settlement with the Department of Justice over a cybersecurity breach. To add to the pile: sanctions in China and the Trump administration cutting National Institutes of Health (NIH) funding, which the company relies heavily on for clinical research. The numbers don't lie. The stock is down more than 21% in the past year and sank more than 11% in after-hours trading Thursday after the company reported an earnings miss for the second quarter. The company reported $1.06 billion in revenues compared to expected revenues of $1.05 billion. Adjusted earnings per share came in at $1.19 compared to estimates of $1.01. But CEO Jacob Thaysen told Yahoo Finance he remains positive about the company's near-term growth. Why? Because, in part, pharmaceutical companies can provide a new market. "Now, we're shifting from small things to really big programs. Some of the things making up for the reduction from the NIH is kind of indirect, but pharma is getting more interest in these big programs," he said, noting that 15% of the company is exposed to government research funding. "It's not only about sequencing itself, but really using massive amounts of data ... to really identify new drug targets and understand a disease," Thaysen said. The idea to use patient data to help the pharmaceutical world was also identified by 23andMe, which recently came out of bankruptcy through a nonprofit led by founder Anne Wojcicki. Thaysen said that unlike 23andMe, which he has worked with, his company is not going to pursue drug development on its own. "We have a lot of pharma companies that are very excited to work with us," he said. In addition to genetic testing of patient samples, the company is looking at growing in the preventative side of care with cancer screenings. The oncology business, Thaysen said, will have healthy growth over the next 10 or so years. China China banned importations of the San Diego-based company's sequencing machines earlier this year as part of its retaliatory actions to Trump's tariff war. Thaysen said he is working with regulators to try to reverse that, but "in the meantime, that business is declining, and we are expecting it to be flat." In fact, though China has historically been about 10% of the company's business, it contributed to half of the decline in earnings this past week. "China was never a huge part of Illumina's business. When it was the largest, it was just around 10%. We're down to 5% of the business," Thaysen told Yahoo Finance. But because of the tariff war and China's goals to boost its domestic innovation market, Illumina has faced a setback in its market power there from local competition. "As soon as there is a Chinese alternative that is good enough, then you will see that the Chinese government is pushing for the Chinese population, the Chinese companies to use that technology," Thaysen said. He added that even with the increased competition, China is an appealing market to remain in. Analysts are still waiting to see more progress on Illumina's return to growth. Jefferies analyst Tycho Peterson said in a note to clients that the firm will reiterate its Hold rating until things settle: "While the clinical traction is encouraging, we view clarity on near-term headwinds (A&G, China, Roche) and a path to sustainable HSD growth as key to a more constructive view. Reiterate Hold." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Stryker lowers expected tariff impact to $175M
Stryker lowers expected tariff impact to $175M

Yahoo

time2 hours ago

  • Yahoo

Stryker lowers expected tariff impact to $175M

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $6 billion 11.1% increase year over year Net income: $884 million 7.2% increase year over year Stryker expects a $175 million tariff impact on earnings in 2025, a slight decrease from the $200 million the company forecast in May. Stryker joins several medical device companies that have slashed tariff expectations, with several firms, including Johnson & Johnson and Boston Scientific, cutting the expected tariff hit by as much as half. Stryker CFO Preston Wells said Thursday on an earnings call that the changes were a result of the U.S. and China agreeing to significantly reduce levies. However, Stryker did not cut its forecast by as much as other companies because the recent trade agreement with the European Union, which set a tariff rate of 15%, was more than the 10% Stryker had included in its previous model. CEO Kevin Lobo said Stryker was impacted less than other companies due to its manufacturing footprint in Europe and having less of a presence in China than other medtech companies. Raised earnings forecast Stryker raised its financial forecast for the year, now expecting organic sales growth in a range of 9.5% to 10%, from a previous range of 8.5% to 9.5%. The company also raised its expectations for adjusted earnings per share by about 20 cents. Lobo said the update was driven by continued procedural strength, including implants, and demand for capital equipment. Wells said initiatives Stryker started during the COVID-19 pandemic, such as pricing and manufacturing efficiency, have helped drive margin improvements. Robot update Stryker shared an update on planned launches for the company's robots. In March, the company unveiled its latest orthopedic robot, the Mako 4. The Food and Drug Administration cleared the new system, but Stryker has not yet rolled out the robot globally, Lobo said. The company has new hip revision and spine surgery applications that are only available on Mako 4. Stryker's shoulder surgery application is currently on its Mako 3 robot, and is in the process of migrating to the newer robot, Lobo said. Because of that, the feature is still in a limited launch until next year. Stryker reported a record quarter for Mako installations, although the company did not disclose the number of robots. The company reached a milestone of 2 million robotic procedures performed with Mako during the second quarter. Recommended Reading Stryker expects $200M tariff hit, lowers earnings forecast Sign in to access your portfolio

Lufax Holding Ltd (LU) Sells $64M in Bad Loans to Cut Credit Risk, Stabilize Outlook
Lufax Holding Ltd (LU) Sells $64M in Bad Loans to Cut Credit Risk, Stabilize Outlook

Yahoo

time2 hours ago

  • Yahoo

Lufax Holding Ltd (LU) Sells $64M in Bad Loans to Cut Credit Risk, Stabilize Outlook

We recently compiled a list of the 10 Best Low Cost Stocks To Buy Under $50. Lufax Holding Ltd stands fourth on our list. Lufax Holding Ltd (NYSE:LU), a leading Chinese fintech firm serving small and micro businesses, is undergoing strategic shifts to navigate a challenging market in 2025. A key recent development was the sale of non-performing loans (NPLs) through its subsidiary, Ping An Consumer Finance. The transaction involved offloading 469 million yuan in NPLs for 36.44 million yuan to Sh China Merch Ping An Asset Management. This move reduced credit risk and supported a drop in the company's loan portfolio by 18%, helping stabilize investor sentiment amid asset quality concerns. In addition to asset optimization, Lufax Holding Ltd (NYSE:LU) is focusing on digital transformation through new partnerships and AI-driven innovation. These efforts aim to boost operational efficiency and profitability while enhancing its competitive edge in a crowded fintech market. The business is also pursuing cost-cutting measures as part of a broader strategy to improve earnings. Despite these positive steps, cheap stocks to buy like Lufax Holding Ltd (NYSE:LU) saw sharp declines in late July, dropping over 11% and 12% on back-to-back days. The sell-off reflected investor concerns over limited near-term catalysts and persistent pressure from traditional banks. An individual using a laptop to access the fintech platform to manage their finances. Looking ahead, the corporation plans to continue managing credit risk proactively, expand its digital offerings, and pursue strategic partnerships. These efforts are expected to support earnings growth and may enable the resumption of dividends by the end of the 2025 fiscal year. While we acknowledge the potential of LU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store